ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2012
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study.
Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 61 citations in OpenAlex.
- Expanding the liver donor pool worldwide with hepatitis C infected livers, is it the time?World journal of transplantation · 2024Review
- Analysis of hepatitis C virus-positive organs in liver transplantation.World journal of hepatology · 2022Article
- Impact of utilization of hepatitis C positive organs in liver transplant: Analysis of united network for organ sharing database.World journal of hepatology · 2022Article
- Update on liver transplantation-newer aspectsTurkish journal of medical sciences · 2020Review
- Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019Article
- Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients.Digestive diseases and sciences · 2019Review
- Recent advances in liver transplantation with HCV seropositive donors.F1000Research · 2019Review
- Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.Transplant infectious disease : an official journal of the Transplantation Society · 2018Article
- Cost Effectiveness of Pre- vs Post-Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2018Article
- Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.Hepatology (Baltimore, Md.) · 2017Article
- Use of Hepatitis C-Positive Donor Livers in Liver Transplantation.Current hepatology reports · 2017Article
- Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor.BMC gastroenterology · 2016Article
- Key donor factors associated with graft loss among liver transplant recipients with human immunodeficiency virus.Clinical transplantation · 2016Article
- Hepatitis C virus-HIV-coinfected patients and liver transplantation.Current opinion in organ transplantation · 2015Review
- Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.World journal of gastroenterology · 2014Review
- Recurrent hepatitis C after liver transplant.World journal of gastroenterology · 2014Review
- Expanded criteria donors.Clinics in liver disease · 2014Review
- Expanding the donor pool in liver transplantation: Extended criteria donors.Clinical liver disease · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
Over the last decade, the use of liver grafts from hepatitis C virus antibody-positive donors [HCV(+)Ds] has tripled in the United States. Although previous studies have demonstrated no association between an HCV(+)D status and graft loss, the effects of an HCV(+)D on histological outcomes are not well known. Hepatitis C virus (HCV)-infected recipients at 5 US centers (2002-2007) who survived more than 30 days with 1 or more posttransplant biopsy samples were included. Cox regression was used to examine the association between an HCV(+)D status and advanced fibrosis (stage 3/4 or higher). Ninety-nine of the 1206 patients (8%) received an HCV(+)D graft. Recipients of HCV(+)D grafts were older than recipients of hepatitis C virus antibody-negative donor [HCV(-)D] grafts (P = 0.03), but they were otherwise similar. HCV(+)D grafts were significantly lower in quality according to the donor risk index (P < 0.001). Advanced fibrosis occurred in 32% of HCV(+)D graft recipients and in 28% of HCV(-)D graft recipients (P = 0.39). The unadjusted 1- and 3-year rates of advanced fibrosis were significantly higher for HCV(+)D graft recipients (14% and 48%) versus HCV(-)D graft recipients (7% and 33%, P = 0.01). Transplantation with HCV(+)D grafts was associated with a 58% increased risk of advanced fibrosis [95% confidence interval (CI) = 1.05-2.36, P = 0.03]. However, in an analysis stratified by the mean donor age of 45 years, an HCV(+)D status was associated with advanced fibrosis only with donors >45 years old [hazard ratio (HR) = 1.76, 95% CI = 1.06-2.93, P = 0.03] and not with donors ≤45 years old (HR = 0.94, 95% CI = 0.47-1.87, P = 0.85). In conclusion, a careful consideration of the risks and benefits is needed with HCV(+)D grafts. Recipients of HCV(+)D grafts (especially from older donors) should undergo close monitoring for more rapidly progressive fibrosis. Studies are needed to determine whether early HCV therapy modifies this risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.